Combining targeted therapies in ovarian cancer

Menée sur 90 patientes atteints d'un cancer récidivant de l'ovaire sensible aux sels de platine, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du cediranib, un agent anti-angiogénique, à l'olaparib, un inhibiteur de PARP

Résumé en anglais

Use of targeted agents with cytotoxic drugs in a maintenance setting should revolutionise treatment strategies for patients with relapsed ovarian cancer. Results from several randomised trials in first-line and salvage settings report the efficacy of anti-angiogenic agents in platinum-based combinations for prolonging progression-free survival (PFS) and overall survival. Studies have shown the therapeutic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in patients with BRCA -mutated ova ...